Does sunscreen prevent skin cancer? What the Australian trial can tell us

Regular sunscreen is one part of sun protection. Read the long-term randomized evidence without turning a small melanoma result into a guarantee.

Prepared by PoshanSense · AI-assisted educational writing
Our sources and editorial approach · Not clinically reviewed

Research explained · Published 2011

Sunscreen advice often arrives as a slogan: wear it every day, prevent cancer. The practical advice can be sensible while the study behind it remains more nuanced. Understanding both helps avoid two extremes—dismissing protection or treating a bottle as a shield against unlimited sun.

Should sunscreen be your only protection?

No. Current NHS guidance puts sunscreen alongside shade and suitable clothing. It recommends at least SPF30 with appropriate UVA protection and reapplication as directed, especially after swimming or sweating.

The relevance of protection depends on exposure and UV conditions, not simply whether the day feels hot. Advice about the clock in one country should not be copied as a universal schedule for every latitude and season.

Did daily use reduce melanoma?

The 2011 follow-up report found 11 melanomas in the daily-use group and 22 with discretionary use. The estimated hazard ratio was 0.50, but its uncertainty interval ran from 0.24 to 1.02. That supports a possible benefit while remaining compatible with no clear difference.

For invasive melanoma, there were three versus eleven cases, with an interval favouring daily use. This was a smaller subtype comparison with few events. It should not become a promise that sunscreen cuts every person's cancer risk by a fixed percentage.

The trial received Australian public research funding; an author disclosed research funding from L’Oréal. The main report's funding and disclosures deserve transparency alongside its results.

Why is the result useful despite the uncertainty?

Random assignment offers stronger protection against some biases than simply comparing people who choose to use sunscreen with people who do not. In everyday life, those groups may differ in skin sensitivity, outdoor work, sun exposure and many other habits.

Long follow-up also matters because skin cancer is not an outcome a short skincare experiment can settle. Even here, the small number of melanoma diagnoses means the estimate is imprecise. A strong study design does not remove every uncertainty.

Does an old SPF16 trial mean SPF16 is the recommendation now?

No. The trial describes what was tested in the 1990s, not today's complete product guidance. It also compared regular use with discretionary use, so it cannot quantify sunscreen versus absolutely no protection.

Follow current local guidance and the product's directions rather than copying the old intervention. The amount applied, exposed areas, reapplication and time outside matter to real-world protection. A high label number does not make those details irrelevant.

What about darker skin or a different climate?

The trial's exact effect should not be transferred unchanged to everyone. Different skin types and exposure patterns can change baseline risk and the size of a possible absolute benefit. That limitation is not a reason to assume skin cancer cannot occur in darker skin.

Keep an eye on new or changing skin lesions and seek medical assessment when appropriate. Sunscreen is prevention support, not a way to diagnose or treat a suspicious mole. There is also no need to deliberately accumulate UV exposure to test whether a product works.

A useful takeaway is ordinary and achievable: match protection to actual exposure, combine methods and avoid the idea that sunscreen buys extra safe time in intense sun. Educational article; not clinically reviewed.

Published 11 October 2026 · Sources checked 11 October 2026. Suggest a correction.